NEW YORK, December 29, 2025, 22:14 ET — Market closed
- Amgen fell 1% to $329.63 at the close, extending a choppy late-December stretch.
- U.S. stocks ended lower as big tech retreated ahead of the New Year.
- Investors are watching Fed minutes, jobless claims and the next update on Amgen’s obesity drug program.
Amgen shares fell 1% on Monday, ending the session down $3.30 at $329.63.
The decline matters now because traders are heading into the final sessions of the year with U.S. indexes near record territory and liquidity thinner than usual. That backdrop can amplify moves in large-cap healthcare stocks even without a company-specific trigger.
Wall Street’s main indexes closed lower, led by a retreat in heavyweight technology names, Reuters reported. “It’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust, describing the dip in tech shares. Reuters
Amgen broadly moved with the market, as investors repositioned across sectors into month- and year-end. The S&P 500 fell 0.35% and the Nasdaq dropped 0.50%, according to Reuters.
For Amgen, attention remains on its obesity candidate MariTide, a drug aimed at the GLP-1 pathway that has powered blockbuster weight-loss therapies. Amgen said Phase 2 studies in chronic weight management and type 2 diabetes are expected to deliver data in the fourth quarter of 2025.
Phase 2 trials are mid-stage studies designed to test dosing and early effectiveness in patients, while Phase 3 trials are larger studies used to confirm results before regulators consider approval. Amgen said multiple Phase 3 “MARITIME” studies are under way across weight management and cardiometabolic outcomes. Amgen
The company last updated investors on its financial outlook in early November, when it raised its 2025 forecast. Amgen projected adjusted (non-GAAP) earnings of $20.60 to $21.40 per share on revenue of $35.8 billion to $36.6 billion, the company said.
Analysts, on average, expected 2025 earnings of $21.04 per share, Reuters reported at the time.
Amgen’s obesity push is set against Novo Nordisk and Eli Lilly, whose GLP-1 medicines have reshaped demand across the sector. On Monday, Novo Nordisk fell about 1.8% while Lilly edged up about 0.2%, according to market data.
Macro catalysts are also on deck. Minutes from the Federal Reserve’s prior meeting and a weekly reading on U.S. jobless claims are among the key items on traders’ radar this week, Reuters reported.
Before Tuesday’s session, chart-watchers are focused on whether Amgen holds the $330 area after Monday’s low of $329.47. A move back above Monday’s $333.50 high would be an early test of near-term resistance.
Beyond that, the stock sits about 5% below its early-December high of $346.38, while December’s low near $312.39 is a key downside reference point from recent trading.
The next major scheduled company catalyst is Amgen’s quarterly report; Nasdaq’s earnings calendar estimates the company will report around Feb. 3. Investors are expected to focus on any update to 2026 guidance and the timing of MariTide readouts as the weight-loss race tightens.
